#1 Clinical Trials Search in Europe

Tiratricol

Tiratricol, also known as Triac, is being investigated as a potential treatment for patients with monocarboxylate transporter 8 (MCT8) deficiency, also called Allan-Herndon-Dudley syndrome (AHDS). This rare genetic disorder affects thyroid hormone transport and leads to severe intellectual and motor disabilities. Clinical trials are exploring the effects of tiratricol on neurodevelopment, thyroid hormone levels, and other symptoms associated with MCT8 deficiency.

Table of Contents

What is Tiratricol?

Tiratricol, also known by its other names Triac, Téatrois, or TA3, is a thyroid hormone analog. This means it’s a medication that mimics the action of thyroid hormones in the body. Tiratricol is a naturally occurring metabolite (breakdown product) of T3, which is one of the main thyroid hormones[1]. It has similar biological activity and binds to the same receptors in the body as T3, making it a promising treatment for certain thyroid-related disorders.

What Conditions Does Tiratricol Treat?

Tiratricol is being studied primarily for the treatment of a rare genetic condition called Monocarboxylate Transporter 8 (MCT8) Deficiency. This condition is also known as Allan-Herndon-Dudley Syndrome (AHDS)[2]. MCT8 deficiency is caused by mutations in the MCT8 gene, which is responsible for transporting thyroid hormones into cells, especially in the brain[1].

People with MCT8 deficiency experience a range of symptoms, including:

  • Severe intellectual and motor disabilities: This is due to a lack of thyroid hormones in the brain, leading to impaired brain development.
  • Low body weight and reduced muscle mass: This is caused by high levels of thyroid hormones in other parts of the body.
  • Abnormal thyroid hormone levels in the blood: Typically, these patients have high T3, low T4, and normal TSH levels[1].

How Does Tiratricol Work?

Tiratricol works in a unique way that makes it particularly suitable for treating MCT8 deficiency:

  1. Independent transport: Unlike regular thyroid hormones, Tiratricol doesn’t rely on the MCT8 transporter to enter cells. This means it can reach tissues that are normally deprived of thyroid hormones in MCT8 deficiency, including the brain[3].
  2. Similar action to T3: Once inside the cells, Tiratricol binds to the same receptors as T3, potentially restoring normal thyroid hormone function[1].
  3. Normalization of thyroid levels: Tiratricol treatment aims to reduce the high T3 levels in the blood, which can help alleviate some of the symptoms caused by thyroid hormone excess in certain tissues[3].

How is Tiratricol Administered?

Tiratricol is available as tablets containing 350 micrograms of the medication. It can be administered in several ways:

  • Oral administration: The tablets are suspended in water and can be mixed with food if needed.
  • Tube feeding: For patients who cannot take medication by mouth, Tiratricol can be given through a percutaneous endoscopic gastrostomy (PEG) tube, nasogastric tube, or jejunal tube[2].

The dosage is individually tailored for each patient, starting with a low dose and gradually increasing to reach the optimal level[1].

Current Clinical Trials

Several clinical trials are currently underway to evaluate the effectiveness and safety of Tiratricol in treating MCT8 deficiency:

  • Expanded Access Program: This program aims to provide Tiratricol to patients with MCT8 deficiency before it receives marketing authorization[2].
  • Triac Trial II: This study is investigating the effects of Tiratricol on young boys (30 months or younger) with MCT8 deficiency[3].
  • Withdrawal Study: This trial is examining what happens when Tiratricol treatment is stopped in patients who have been receiving it[4].

Potential Benefits of Tiratricol

Based on current research, Tiratricol may offer several benefits for patients with MCT8 deficiency:

  • Improved brain development: By providing thyroid hormone-like activity to the brain, Tiratricol may help improve cognitive and motor function[3].
  • Normalized thyroid hormone levels: Tiratricol treatment aims to reduce the high T3 levels in the blood, which can help alleviate symptoms of thyroid hormone excess in certain tissues[1].
  • Better growth and muscle development: By addressing the thyroid hormone imbalance, Tiratricol may help improve body weight and muscle mass[1].
  • Improved heart function: Tiratricol may help normalize heart rate and other cardiovascular parameters affected by thyroid hormone imbalance[4].

Possible Side Effects and Monitoring

While Tiratricol shows promise, it’s important to monitor patients closely for potential side effects. During clinical trials, researchers are keeping track of:

  • Thyroid hormone levels: Regular blood tests are conducted to ensure thyroid hormone levels remain within the target range[4].
  • Heart function: ECGs and heart rate monitoring are performed to check for any cardiac effects[1].
  • Liver function: Blood tests are done to monitor liver enzymes and other markers of liver health[4].
  • Bone density: Some studies are measuring bone mineral density to ensure Tiratricol doesn’t negatively affect bone health[1].
  • General health: Patients are monitored for any adverse events or unexpected side effects throughout the treatment period[2].

It’s important to note that as Tiratricol is still being studied, all potential side effects may not be known yet. Patients receiving this treatment should be in close contact with their healthcare providers and report any unusual symptoms promptly.

Aspect Details
Drug Name Tiratricol (also known as Triac)
Target Condition MCT8 deficiency (Allan-Herndon-Dudley Syndrome)
Mechanism of Action Thyroid hormone analog that can enter cells without MCT8 transporter
Primary Outcomes Neurodevelopment, thyroid hormone levels, motor function
Secondary Outcomes Heart rate, body weight, blood pressure, cholesterol levels
Trial Durations Typically 1-4 years
Patient Age Groups Young children to adults
Administration Oral tablets or through feeding tubes
Safety Monitoring Adverse events, cardiac function, bone mineral density

FAQ

  • What is MCT8 deficiency? MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome (AHDS), is a rare genetic disorder that affects thyroid hormone transport. It results in a lack of thyroid hormone in the brain, causing severe intellectual and motor disabilities, as well as high thyroid hormone levels in the blood.
  • How does tiratricol work in treating MCT8 deficiency? Tiratricol is a thyroid hormone analog that can enter cells without relying on the MCT8 transporter. It aims to restore thyroid hormone function in tissues that depend on MCT8, such as the brain, while also helping to normalize thyroid hormone levels in the blood.
  • What are the main goals of the clinical trials using tiratricol? The main goals of the clinical trials are to evaluate the effects of tiratricol on neurodevelopment, thyroid hormone levels, and other symptoms associated with MCT8 deficiency. Researchers are looking at improvements in motor function, cognitive abilities, and biochemical markers of thyroid hormone status.
  • Are there any potential side effects of tiratricol treatment? While the clinical trials are ongoing, researchers are monitoring for potential side effects. Common assessments include heart function, bone mineral density, and overall safety. Patients are closely monitored for any adverse events throughout the treatment period.
  • How long do the clinical trials for tiratricol typically last? The duration of clinical trials for tiratricol varies, but many studies last for at least one year to assess long-term effects. Some trials, like the Triac Trial II, have an initial treatment period of 96 weeks, followed by an additional 2-year follow-up to evaluate long-term outcomes.

Ongoing Clinical Trials on Tiratricol

  • Study of tiratricol treatment in children with MCT8 deficiency (Monocarboxylate Transporter 8 deficiency) to improve motor development

    Not recruiting

    1 1
    Investigated drugs:
    Czechia The Netherlands

  • Study of Tiratricol Treatment Withdrawal in Males with MCT8 Deficiency (Monocarboxylate Transporter 8 Deficiency)

    Not recruiting

    1 1
    Investigated drugs:
    The Netherlands

Glossary

  • Tiratricol: A thyroid hormone analog also known as Triac or 3,3',5-triiodothyroacetic acid. It is being studied as a potential treatment for MCT8 deficiency.
  • MCT8 deficiency: A rare genetic disorder affecting thyroid hormone transport, also known as Allan-Herndon-Dudley syndrome (AHDS). It causes severe intellectual and motor disabilities.
  • Allan-Herndon-Dudley Syndrome (AHDS): Another name for MCT8 deficiency, named after the researchers who first described the condition.
  • Thyroid hormone: Hormones produced by the thyroid gland that are essential for normal growth, development, and metabolism.
  • T3 (Triiodothyronine): The active form of thyroid hormone, which is often elevated in the blood of patients with MCT8 deficiency.
  • T4 (Thyroxine): The main form of thyroid hormone produced by the thyroid gland, which is often low in patients with MCT8 deficiency.
  • TSH (Thyroid Stimulating Hormone): A hormone produced by the pituitary gland that regulates thyroid hormone production.
  • Neurodevelopment: The growth and development of the brain and nervous system, which is significantly impaired in MCT8 deficiency.
  • Gross Motor Function: The ability to control large muscle movements, such as walking or sitting up, which is often severely affected in MCT8 deficiency.
  • Expanded Access Program: A program that allows patients with serious or life-threatening conditions to access investigational treatments before they are approved by regulatory agencies.

References

  1. https://clinicaltrials.gov/study/NCT02060474
  2. https://clinicaltrials.gov/study/NCT05911399
  3. https://clinicaltrials.eu/trial/study-on-tiratricol-for-children-with-mct8-deficiency/
  4. https://clinicaltrials.gov/study/NCT05579327